Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRESS-Norway: Precision Medicine in Public Cancer Care
2020-004414-35Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alpelisib, fulvestrant, imatinib, hydroxyurea, bortezomib and 5 more in cancer, sponsored by Oslo University Hospital. Primary endpoint: Percentage of patients included and treated based on molecular tumour profile. Started Sep 2020; status: active.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2020-004414-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004414-35.